| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.01 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | SCH-529074 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | -0.086 | 0.01 |
| mRNA | RAF265 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | CUDC-101 | GDSC1000 | pan-cancer | AAC | -0.078 | 0.01 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |